Evoke Pharma’s (EVOK) “Buy” Rating Reiterated at HC Wainwright

Evoke Pharma, Inc. (NASDAQ:EVOK)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Tuesday. They presently have a $9.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 247.49% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. FBR & Co reiterated a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a research report on Thursday, May 18th. ValuEngine upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.25.

Shares of Evoke Pharma (NASDAQ:EVOK) traded up 0.39% during trading on Tuesday, hitting $2.59. 16,601 shares of the company’s stock were exchanged. The company’s market cap is $39.85 million. Evoke Pharma has a 12-month low of $1.35 and a 12-month high of $4.55. The company has a 50-day moving average of $2.44 and a 200-day moving average of $2.72.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.15. During the same quarter last year, the business posted ($0.41) EPS. On average, equities analysts expect that Evoke Pharma will post ($0.86) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/18/hc-wainwright-analysts-give-evoke-pharma-inc-evok-a-9-00-price-target.html.

Large investors have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. purchased a new stake in Evoke Pharma during the first quarter valued at about $1,550,000. State Treasurer State of Michigan boosted its stake in Evoke Pharma by 62.2% in the first quarter. State Treasurer State of Michigan now owns 291,966 shares of the specialty pharmaceutical company’s stock valued at $905,000 after buying an additional 111,966 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after buying an additional 68,544 shares during the last quarter. Hedge funds and other institutional investors own 12.37% of the company’s stock.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

What are top analysts saying about Evoke Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evoke Pharma Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit